Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19 infection
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0259909
Abstract
This study investigated the association between COVID-19 infection and host metabolic signatures as prognostic markers for disease severity and mortality. We enrolled 82 patients with RT-PCR confirmed COVID-19 infection who were classified as mild, moderate, or severe/critical based upon their WHO clinical severity score and compared their results with 31 healthy volunteers. Data on demographics, comorbidities and clinical/laboratory characteristics were obtained from medical records. Peripheral blood samples were collected at the time of clinical evaluation or admission and tested by quantitative mass spectrometry to characterize metabolic profiles using selected metabolites. The findings in COVID-19 (+) patients reveal changes in the concentrations of glutamate, valeryl-carnitine, and the ratios of Kynurenine/Tryptophan (Kyn/Trp) to Citrulline/Ornithine (Cit/Orn). The observed changes may serve as predictors of disease severity with a (Kyn/Trp)/(Cit/Orn) Receiver Operator Curve (ROC) AUC = 0.95. Additional metabolite measures further characterized those likely to develop severe complications of their disease, suggesting that underlying immune signatures (Kyn/Trp), glutaminolysis (Glutamate), urea cycle abnormalities (Cit/Orn) and alterations in organic acid metabolism (C5) can be applied to identify individuals at the highest risk of morbidity and mortality from COVID-19 infection. We conclude that host metabolic factors, measured by plasma based biochemical signatures, could prove to be important determinants of Covid-19 severity with implications for prognosis, risk stratification and clinical management.Keywords
Funding Information
- Nagourney Institute (ID# 95-4731388, Grant 001-2021)
- National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (UL1 TR001414)
This publication has 29 references indexed in Scilit:
- Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data AnalysisCurrent Protocols in Bioinformatics, 2019
- An Updated Review of Lysophosphatidylcholine Metabolism in Human DiseasesInternational Journal of Molecular Sciences, 2019
- Influence of collection tubes during quantitative targeted metabolomics studies in human blood samplesClinica Chimica Acta, 2018
- Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohortsEuropean Journal of Epidemiology, 2017
- Correction: Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to TreatmentPLOS ONE, 2017
- Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics studyBMC Medicine, 2016
- Reliability of Serum Metabolites over a Two-Year Period: A Targeted Metabolomic Approach in Fasting and Non-Fasting Samples from EPICPLOS ONE, 2015
- Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic ApproachDiabetes, 2013
- Suggested guidelines for the diagnosis and management of urea cycle disordersOrphanet Journal of Rare Diseases, 2012
- Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological SettingPLOS ONE, 2010